Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4423ec77cbc8dab9d0a98909704e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-242 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-242 |
filingDate |
2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_679284a4a1a3a2d162baac4ee378b454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d85cb66b3149a129925fda88a30691d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85eb6b815ff3be21a4566e8924a2a84b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_374466b3a0b5460920e8f55a112d17cd |
publicationDate |
2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019240186-A1 |
titleOfInvention |
Gold nanoparticle based formulation for use in cancer therapy |
abstract |
The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114432441-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021215952-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114533868-A |
priorityDate |
2016-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |